For research use only. Not for therapeutic Use.
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research[1].
| Catalog Number | I040388 |
| CAS Number | 2543693-10-1 |
| Purity | ≥95% |
| Reference | [1]. Henry Chan, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood (2021) 138 (Supplement 1): 2271. |
